TuHURA Reports Q3 2026 Results, Advances Clinical Programs

TuHURA reported Q3 2026 results with $1.9M in cash, $9.2M from credit facility, and reduced R&D expenses. Progress in IFx-2.0 and TBS-2025 programs, including FDA clearance for Phase 1b study of TBS-2025. Expects preliminary data in 2027.

Original reporting
Published Nov 13, 2026, 12:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 1:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
TuHURA Reports Q3 2026 Results, Advances Clinical Programs — source image
Decision brief

The 30-second read

$HURABullishMed
01

Why it matters

The FDA clearance for TBS-2025 and the $9.2M financing are fresh, material events that could move the stock.

02

Market read

First‑report of quarterly results and regulatory clearance for a micro‑cap biotech, offering a new catalyst for traders.

03

What to watch

Potential competition in the AML space and the need for further data to de‑risk the program.

Relevance 7/10Novelty 7/10Timing: post‑market today

Background

TuHURA Biosciences is a clinical‑stage biotech developing bispecific antibodies for oncology. The Q3 filing includes financials and updates on its pipeline.

Company-level read

Ticker impact

$HURABullishHigh confidence
Context

TuHURA Biosciences reported Q3 2026 results, including FDA clearance to begin a Phase 1b study of TBS-2025 in AML and raised $9.2M under its credit facility.

Expected impact

potential upward pressure as investors price in the FDA clearance and additional financing.

Evidence & confidence

First disclosure of a regulatory clearance and fresh financing for a micro‑cap biotech typically triggers buying interest.

Market effects

Positive signal for the broader biotech sector focused on AML and bispecific antibodies.

Limited to U.S. biotech investors; no broader regional effect.

Minor, as the company is a micro‑cap with niche therapeutic focus.

Counterpoint

The small cash balance and ongoing cash burn could limit near‑term execution, keeping the stock vulnerable.

Key entities

  • TuHURA Biosciences, Inc.

    Clinical‑stage biotech developing IFx-2.0 and TBS-2025 programs.

Related articles

$HURAMed

TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update TAMPA, Fla., Nov. 13, 2026 -- TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance

$HURAMed

TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

TuHURA Biosciences (NASDAQ: HURA) reported Q3 2026 results, highlighting progress in its immuno-oncology programs. The company shared early data from its IFx-2.0 study with Keytruda, showing durable responses in Merkel cell carcinoma patients. It also received FDA clearance for a Phase 1b study of its VISTA-inhibiting antibody, TBS-2025, in a subset of AML. TuHURA has $1.9M in cash and access to a $50M credit facility.

$HURAMedAI 8/10

TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study

TuHURA Biosciences reported early responses in a study of its immunotherapy IFx-2.0 for deep-seated Merkel cell cancer. Preliminary results showed potential for use with checkpoint inhibitors, with five of eight patients in a prior study achieving durable responses. The company is conducting a Phase III trial comparing IFx-2.0 plus pembrolizumab to placebo, with enrollment expected to complete by Q3 or Q4 2024. TuHURA aims to discuss regulatory options with the FDA if data remains favorable.

$HURAHighAI 8/10

TuHURA reports tumor responses in 3-patient cancer trial

TuHURA Biosciences (HURA) reported partial tumor responses in 3 patients from a trial of IFx-2.0 combined with Keytruda for metastatic Merkel Cell Carcinoma. The Phase 1b/2a trial aims to enroll 9 patients and assesses safety and feasibility. The company is also conducting a Phase 3 trial. HURA hosted a webcast to discuss the initial data.

$HURALow

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

TuHURA Biosciences (NASDAQ:HURA) received a U.S. patent for its Delta Opioid Receptor (DOR) technology, covering uses in cancer treatments, including ADCs and cellular immunotherapies. The patent, valid until 2043, aims to enhance cancer immunotherapy effectiveness by targeting MDSCs. TuHURA is advancing preclinical models for blood-related cancers like AML and MDS.